Limits...
Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.

Luo X, Li XM, Hu ZY, Cheng ZN - Acta Pharmacol. Sin. (2009)

Bottom Line: No significant changes in AUC(F) (P=0.178), or in the amount of urinary 6beta-OHF (P=0.169), or in F (P=0.391) were found over a 24 h time period, either with or without MDZ administration.Although Cl(m(6beta)) and 6beta-OHF/F can reflect the decline in CYP3A activity, the impression they provide is neither accurate nor complete.AUC(F) is completely ineffective for evaluating variations in CYP3A activity.

View Article: PubMed Central - PubMed

Affiliation: Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.

ABSTRACT

Aim: Currently, there is considerable debate as to which method is more accurate for measuring the activity of CYP3A in vivo: cortisol 6beta-hydroxylation clearance (Cl(m(6beta))) or the urinary ratio of 6beta-OHF to F (6beta-OHF/F). Furthermore, the value of measuring endogenous levels of cortisol over a 24 h period (AUC(F)) needs to be confirmed. The aim of the present study was to determine which method was most effective at measuring changes in the in vivo activity of CYP3A: AUC(F), Cl(m(6beta)), or 6beta-OHF/F.

Methods: A two phase, cross-over design was adopted in this study. A total of 24 subjects (12 males and 12 females) were randomly assigned to one of two groups: the test group subjects were given 250 mg clarithromycin tablets twice a day for a period of 4 d, whereas the control group received a placebo twice daily for a similar period. On d 5 of the study, the last dose of either clarithromycin or placebo was supplemented with an oral dose of 7.5 mg midazolam (MDZ); blood and urine samples were then collected at various times. All samples collected at the same sampling times on d 4 were used to evaluate the effects of MDZ administration on cortisol levels and metabolism. The ratio of 1-hydroxymidazolam (1-OHMDZ) concentration to MDZ concentration at 1 h (MR) was taken as a measure of the in vivo CYP3A activity. AUC(F), Cl(m(6beta)), and 6beta-OHF/F were also used as biomarkers for CYP3A activity.

Results: No correlations were found (either before or after inhibition) between CYP3A activity and any of the following measures: AUC(F), Cl(m(6beta)), or 6beta-OHF/F (r<0.4, P>0.05). After 4 d of clarithromycin administration, CYP3A activity (MR) decreased by 75% (P=0.000), whereas AUC(F) increased by 19% (P=0.040), and Cl(m(6beta)) and 6beta-OHF/F decreased by 54.2% (P=0.000) and 50% (P=0.003), respectively. No significant changes in AUC(F) (P=0.178), or in the amount of urinary 6beta-OHF (P=0.169), or in F (P=0.391) were found over a 24 h time period, either with or without MDZ administration.

Conclusion: Although Cl(m(6beta)) and 6beta-OHF/F can reflect the decline in CYP3A activity, the impression they provide is neither accurate nor complete. AUC(F) is completely ineffective for evaluating variations in CYP3A activity. MDZ administration had no evident effects on either cortisol metabolism or excretion over a period of 24 h.

Show MeSH
(A) Correlation between Clm(6β) and CYP3A activity before inhibition by clarithromycin (n=24); (B) Correlation between Clm(6β) and CYP3A activity after inhibition by clarithromycin (n=24); (C) Correlation between the change in Clm(6β) and CYP3A activity (n=24). MR: the plasma concentration ratio of 1-OHMDZ to MDZ at 1 h.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4007188&req=5

fig4: (A) Correlation between Clm(6β) and CYP3A activity before inhibition by clarithromycin (n=24); (B) Correlation between Clm(6β) and CYP3A activity after inhibition by clarithromycin (n=24); (C) Correlation between the change in Clm(6β) and CYP3A activity (n=24). MR: the plasma concentration ratio of 1-OHMDZ to MDZ at 1 h.

Mentions: MDZ administration caused increases in 6β-OHF urinary excretion of 51% (P=0.022), 75% (P=0.002) and 103% (P=0.019) at 0−4, 4−8, and 8−10 h time-periods, respectively. However, there were no increases in excretion and no alterations in Clm(6β) at 10−24 and 0−24 h time-periods. Following clarithromycin administration, there was a decrease in 6β-OHF urinary excretion at all time-periods, and a reduction in Clm(6β) of 54.2% (P=0.022; Table 3 and Figure 2). However, there were no correlations found between Clm(6β) and MR, either before or after inhibition (r=0.107, P=0.619; r=-0.317, P=0.132, respectively; Figure 4). There was also a lack of a correlation between the change in Clm(6β) and MR (r=0.019, P=0.931; Figure 4).


Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.

Luo X, Li XM, Hu ZY, Cheng ZN - Acta Pharmacol. Sin. (2009)

(A) Correlation between Clm(6β) and CYP3A activity before inhibition by clarithromycin (n=24); (B) Correlation between Clm(6β) and CYP3A activity after inhibition by clarithromycin (n=24); (C) Correlation between the change in Clm(6β) and CYP3A activity (n=24). MR: the plasma concentration ratio of 1-OHMDZ to MDZ at 1 h.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4007188&req=5

fig4: (A) Correlation between Clm(6β) and CYP3A activity before inhibition by clarithromycin (n=24); (B) Correlation between Clm(6β) and CYP3A activity after inhibition by clarithromycin (n=24); (C) Correlation between the change in Clm(6β) and CYP3A activity (n=24). MR: the plasma concentration ratio of 1-OHMDZ to MDZ at 1 h.
Mentions: MDZ administration caused increases in 6β-OHF urinary excretion of 51% (P=0.022), 75% (P=0.002) and 103% (P=0.019) at 0−4, 4−8, and 8−10 h time-periods, respectively. However, there were no increases in excretion and no alterations in Clm(6β) at 10−24 and 0−24 h time-periods. Following clarithromycin administration, there was a decrease in 6β-OHF urinary excretion at all time-periods, and a reduction in Clm(6β) of 54.2% (P=0.022; Table 3 and Figure 2). However, there were no correlations found between Clm(6β) and MR, either before or after inhibition (r=0.107, P=0.619; r=-0.317, P=0.132, respectively; Figure 4). There was also a lack of a correlation between the change in Clm(6β) and MR (r=0.019, P=0.931; Figure 4).

Bottom Line: No significant changes in AUC(F) (P=0.178), or in the amount of urinary 6beta-OHF (P=0.169), or in F (P=0.391) were found over a 24 h time period, either with or without MDZ administration.Although Cl(m(6beta)) and 6beta-OHF/F can reflect the decline in CYP3A activity, the impression they provide is neither accurate nor complete.AUC(F) is completely ineffective for evaluating variations in CYP3A activity.

View Article: PubMed Central - PubMed

Affiliation: Research Institute of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.

ABSTRACT

Aim: Currently, there is considerable debate as to which method is more accurate for measuring the activity of CYP3A in vivo: cortisol 6beta-hydroxylation clearance (Cl(m(6beta))) or the urinary ratio of 6beta-OHF to F (6beta-OHF/F). Furthermore, the value of measuring endogenous levels of cortisol over a 24 h period (AUC(F)) needs to be confirmed. The aim of the present study was to determine which method was most effective at measuring changes in the in vivo activity of CYP3A: AUC(F), Cl(m(6beta)), or 6beta-OHF/F.

Methods: A two phase, cross-over design was adopted in this study. A total of 24 subjects (12 males and 12 females) were randomly assigned to one of two groups: the test group subjects were given 250 mg clarithromycin tablets twice a day for a period of 4 d, whereas the control group received a placebo twice daily for a similar period. On d 5 of the study, the last dose of either clarithromycin or placebo was supplemented with an oral dose of 7.5 mg midazolam (MDZ); blood and urine samples were then collected at various times. All samples collected at the same sampling times on d 4 were used to evaluate the effects of MDZ administration on cortisol levels and metabolism. The ratio of 1-hydroxymidazolam (1-OHMDZ) concentration to MDZ concentration at 1 h (MR) was taken as a measure of the in vivo CYP3A activity. AUC(F), Cl(m(6beta)), and 6beta-OHF/F were also used as biomarkers for CYP3A activity.

Results: No correlations were found (either before or after inhibition) between CYP3A activity and any of the following measures: AUC(F), Cl(m(6beta)), or 6beta-OHF/F (r<0.4, P>0.05). After 4 d of clarithromycin administration, CYP3A activity (MR) decreased by 75% (P=0.000), whereas AUC(F) increased by 19% (P=0.040), and Cl(m(6beta)) and 6beta-OHF/F decreased by 54.2% (P=0.000) and 50% (P=0.003), respectively. No significant changes in AUC(F) (P=0.178), or in the amount of urinary 6beta-OHF (P=0.169), or in F (P=0.391) were found over a 24 h time period, either with or without MDZ administration.

Conclusion: Although Cl(m(6beta)) and 6beta-OHF/F can reflect the decline in CYP3A activity, the impression they provide is neither accurate nor complete. AUC(F) is completely ineffective for evaluating variations in CYP3A activity. MDZ administration had no evident effects on either cortisol metabolism or excretion over a period of 24 h.

Show MeSH